Studies on the antithrombotic action of BOC-D-PHE-PRO-ARG-H (GYKI 14,451)

E. Tremoli, G. Morazzoni, P. Maderna, S. Colli, R. Paoletti

Research output: Contribution to journalArticlepeer-review


Gyki 14,451, a peptide antagonist of thrombin, was tested on an in vivo model of venous thrombosis in the rat. At the 4 and 6 mg/kg i.v. doses, the compound caused a reduction of over 80% in the incidence of thrombus formation, also markedly reducing thrombus weight. Oral administration of Gyki 14,451 (50 and 50+50 mg/kg) did not induce a significant reduction either of thrombosis incidence or of thrombus weight.

Original languageEnglish
Pages (from-to)549-553
Number of pages5
JournalThrombosis Research
Issue number6
Publication statusPublished - Sep 15 1981


  • Experimental venous thrombosis
  • Thrombin inhibitors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology


Dive into the research topics of 'Studies on the antithrombotic action of BOC-D-PHE-PRO-ARG-H (GYKI 14,451)'. Together they form a unique fingerprint.

Cite this